|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Parkin DM, Piñeros M, Znaor A and Bray F: Cancer statistics for the
year 2020: An overview. Int J Cancer. Apr 5–2021.(Epub ahead of
print). View Article : Google Scholar
|
|
2
|
Cao M and Chen W: Epidemiology of lung
cancer in China. Thorac Cancer. 10:3–7. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Skřičková J, Kadlec B, Venclíček O and
Merta Z: Lung cancer. Cas Lek Cesk. 157:226–236. 2018.PubMed/NCBI
|
|
4
|
Myers DJ and Wallen JM: Lung
adenocarcinoma. StatPearls. StatPearls Publishing; Treasure Island,
FL: 2023
|
|
5
|
Blandin Knight S, Crosbie PA, Balata H,
Chudziak J, Hussell T and Dive C: Progress and prospects of early
detection in lung cancer. Open Biol. 7:1700702017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang P, Zhu S, Liang X, Zhang Q, Liu C
and Song L: Revisiting lung cancer metastasis: Insight from the
functions of long non-coding RNAs. Technol Cancer Res Treat.
20:153303382110384882021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Slim A, Kamoun H, Hadidene Y, Smadhi H,
Meddeb A and Megdiche ML: Postoperative recurrence of primary lung
cancer: Anatomo-clinical and therapeutic study. Tunis Med.
99:560–568. 2021.PubMed/NCBI
|
|
8
|
Bresnick AR, Weber DJ and Zimmer DB: S100
proteins in cancer. Nat Rev Cancer. 15:96–109. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Basnet S, Vallenari EM, Maharjan U, Sharma
S, Schreurs O and Sapkota D: An update on S100A16 in human cancer.
Biomolecules. 13:10702023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun X, Wang T, Zhang C, Ning K, Guan ZR,
Chen SX, Hong TT and Hua D: S100A16 is a prognostic marker for
colorectal cancer. J Surg Oncol. 117:275–283. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Saito K, Kobayashi M, Nagashio R, Ryuge S,
Katono K, Nakashima H, Tsuchiya B, Jiang SX, Saegusa M, Satoh Y, et
al: S100A16 is a prognostic marker for lung adenocarcinomas. Asian
Pac J Cancer Prev. 16:7039–7044. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Katono K, Sato Y, Kobayashi M, Nagashio R,
Ryuge S, Igawa S, Ichinoe M, Murakumo Y, Saegusa M and Masuda N:
S100A16, a promising candidate as a prognostic marker for
platinum-based adjuvant chemotherapy in resected lung
adenocarcinoma. Onco Targets Ther. 10:5273–5279. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu C, Yang J, Lin X, Li R and Wu J:
miR-508-5p serves as an anti-oncogene by targeting S100A16 to
regulate AKT signaling and epithelial-mesenchymal transition
process in lung adenocarcinoma cells. Am J Med Sci. 365:520–531.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakano M, Kakiuchi Y, Shimada Y, Ohyama M,
Ogiwara Y, Sasaki-Higashiyama N, Yano N, Ikeda F, Yamada E,
Iwamatsu A, et al: MOV10 as a novel telomerase-associated protein.
Biochem Biophys Res Commun. 388:328–332. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mao CG, Jiang SS, Shen C, Long T, Jin H,
Tan QY and Deng B: BCAR1 promotes proliferation and cell growth in
lung adenocarcinoma via upregulation of POLR2A. Thorac Cancer.
11:3326–3336. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Q, Ma W, Chen S, Tian EC, Wei S, Fan
RR, Wang T, Zhou C and Li T: High integrin α3 expression is
associated with poor prognosis in patients with non-small cell lung
cancer. Transl Lung Cancer Res. 9:1361–1378. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Recillas-Targa F: Cancer epigenetics: An
overview. Arch Med Res. 53:732–740. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kanwal R, Gupta K and Gupta S: Cancer
epigenetics: An introduction. Methods Mol Biol. 1238:3–25. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Katsumata H, Matsumoto K, Yanagita K,
Shimizu Y, Hirano S, Kitajima K, Koguchi D, Ikeda M, Sato Y and
Iwamura M: Expression of S100A16 is associated with biological
aggressiveness and poor prognosis in patients with bladder cancer
who underwent radical cystectomy. Int J Mol Sci. 24:145362023.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen T, Xia DM, Qian C and Liu SR:
Integrated analysis identifies S100A16 as a potential prognostic
marker for pancreatic cancer. Am J Transl Res. 13:5720–5730.
2021.PubMed/NCBI
|
|
23
|
Chen D, Luo L and Liang C: Aberrant
S100A16 expression might be an independent prognostic indicator of
unfavorable survival in non-small cell lung adenocarcinoma. PLoS
One. 13:e01974022018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fang D, Zhang C, Xu P, Liu Y, Mo X, Sun Q,
Abdelatty A, Hu C, Xu H, Zhou G, et al: S100A16 promotes metastasis
and progression of pancreatic cancer through FGF19-mediated AKT and
ERK1/2 pathways. Cell Biol Toxicol. 37:555–571. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang N, Wang R, Tang J, Gao J, Fang Z,
Zhang M, Shen X, Lu L and Chen Y: Calbindin S100A16 promotes renal
cell carcinoma progression and angiogenesis via the VEGF/VEGFR2
signaling pathway. Contrast Media Mol Imaging. 2022:56020112022.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
You X, Li M, Cai H, Zhang W, Hong Y, Gao
W, Liu Y, Liang X, Wu T, Chen F and Su D: Calcium binding protein
S100A16 expedites proliferation, invasion and
epithelial-mesenchymal transition process in gastric cancer. Front
Cell Dev Biol. 9:7369292021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jabłońska-Trypuć A, Matejczyk M and
Rosochacki S: Matrix metalloproteinases (MMPs), the main
extracellular matrix (ECM) enzymes in collagen degradation, as a
target for anticancer drugs. J Enzyme Inhib Med Chem. 31:177–183.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cabral-Pacheco GA, Garza-Veloz I,
Castruita-De la Rosa C, Ramirez-Acuña JM, Perez-Romero BA,
Guerrero-Rodriguez JF, Martinez-Avila N and Martinez-Fierro ML: The
roles of matrix metalloproteinases and their inhibitors in human
diseases. Int J Mol Sci. 21:97392020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dudley AC and Griffioen AW: Pathological
angiogenesis: Mechanisms and therapeutic strategies. Angiogenesis.
26:313–347. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rajabi M and Mousa SA: The role of
angiogenesis in cancer treatment. Biomedicines. 5:342017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Majidpoor J and Mortezaee K: Angiogenesis
as a hallmark of solid tumors-clinical perspectives. Cell Oncol
(Dordr). 44:715–737. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou Q, Chen X, Chen Q and Hao L: Analysis
of angiogenesis-related signatures in the tumor immune
microenvironment and identification of clinical prognostic
regulators in lung adenocarcinoma. Crit Rev Eukaryot Gene Expr.
33:1–16. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Onn A, Bar J and Herbst RS: Angiogenesis
inhibition and lung-cancer therapy. Lancet Oncol. 15:124–125. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Melincovici CS, Boşca AB, Şuşman S,
Mărginean M, Mihu C, Istrate M, Moldovan IM, Roman AL and Mihu CM:
Vascular endothelial growth factor (VEGF)-key factor in normal and
pathological angiogenesis. Rom J Morphol Embryol. 59:455–467.
2018.PubMed/NCBI
|
|
35
|
Chen H, Cong Q, Du Z, Du Z, Liao W, Zhang
L, Yao Y and Ding K: Sulfated fucoidan FP08S2 inhibits lung cancer
cell growth in vivo by disrupting angiogenesis via targeting
VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling. Cancer Lett.
382:44–52. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cheng SS, Yang GJ, Wang W, Leung CH and Ma
DL: The design and development of covalent protein-protein
inter-action inhibitors for cancer treatment. J Hematol Oncol.
13:262020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang D, Hu Z, Xu J, Tang Y, Wang Y, Cai Q
and Zhu Z: MiR-760 enhances sensitivity of pancreatic cancer cells
to gemcitabine through modulating Integrin β1. Biosci Rep.
39:BSR201923582019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
El Messaoudi-Aubert S, Nicholls J,
Maertens GN, Brookes S, Bernstein E and Peters G: Role for the
MOV10 RNA helicase in polycomb-mediated repression of the INK4a
tumor suppressor. Nat Struct Mol Biol. 17:862–868. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
He Q, Zhao L, Liu X, Zheng J, Liu Y, Liu
L, Ma J, Cai H, Li Z and Xue Y: MOV10 binding circ-DICER1 regulates
the angiogenesis of glioma via miR-103a-3p/miR-382-5p mediated ZIC4
expression change. J Exp Clin Cancer Res. 38:92019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li W, Deng X and Chen J: RNA-binding
proteins in regulating mRNA stability and translation: roles and
mechanisms in cancer. Semin Cancer Biol. 86:664–677. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shiota T, Li TC, Nishimura Y, Yoshizaki S,
Sugiyama R, Shimojima M, Saijo M, Shimizu H, Suzuki R, Wakita T, et
al: Integrin α3 is involved in non-enveloped hepatitis E virus
infection. Virology. 536:119–124. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hamidi H and Ivaska J: Every step of the
way: integrins in cancer progression and metastasis. Nat Rev
Cancer. 18:533–548. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cheng S, Li M, Zheng W, Li C, Hao Z, Dai
Y, Wang J, Zhuo J and Zhang L: ING3 inhibits the malignant
progression of lung adenocarcinoma by negatively regulating ITGB4
expression to inactivate Src/FAK signaling. Cell Signal.
117:1110662024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Moye AL, Dost AF, Ietswaart R, Sengupta S,
Ya V, Aluya C, Fahey CG, Louie SM, Paschini M and Kim CF:
Early-stage lung cancer is driven by a transitional cell state
dependent on a KRAS-ITGA3-SRC axis. EMBO J. 43:2843–2861. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tang XR, Wen X, He QM, Li YQ, Ren XY, Yang
XJ, Zhang J, Wang YQ, Ma J and Liu N: MicroRNA-101 inhibits
invasion and angiogenesis through targeting ITGA3 and its systemic
delivery inhibits lung metastasis in nasopharyngeal carcinoma. Cell
Death Dis. 8:e25662017. View Article : Google Scholar : PubMed/NCBI
|
